Freelance Journalist, Investing Reporter

Freelance Journalist, Investing Reporter

The Private Equity Firm That Quietly Profits on Top-Selling Drugs

JULY 8, 2017

All MARCH 21, 2013 - Pressured, Investment Firm Is Said to Skip Fees MAY 16, 2013 - Aiming for the Top, Again DECEMBER 2, 2013 - A Second Act for a Top Wall Street Strategist DECEMBER 5, 2013 - Investors, Dismayed by Losses at Sears, Pull Money From Hedge Fund MARCH 5, 2014 - After a Dazzling Early Career, a Star Trader Settles Down SEPTEMBER 3, 2015 - Philip Falcone, Former Head of Vast Fund, Tries a 3rd Act SEPTEMBER 15, 2016 - Investors Stick With Assets That Mimic Hedge Funds JULY 8, 2017 - The Private Equity Firm That Quietly Profits on Top-Selling Drugs

MARCH 21, 2013 - Pressured, Investment Firm Is Said to Skip Fees MAY 16, 2013 - Aiming for the Top, Again DECEMBER 2, 2013 - A Second Act for a Top Wall Street Strategist DECEMBER 5, 2013 - Investors, Dismayed by Losses at Sears, Pull Money From Hedge Fund MARCH 5, 2014 - After a Dazzling Early Career, a Star Trader Settles Down SEPTEMBER 3, 2015 - Philip Falcone, Former Head of Vast Fund, Tries a 3rd Act SEPTEMBER 15, 2016 - Investors Stick With Assets That Mimic Hedge Funds JULY 8, 2017 - The Private Equity Firm That Quietly Profits on Top-Selling Drugs

Made with ♥ by my son